Efficacy of Botulinum Toxin A Intradetrusor Injections for Non-neurogenic Urinary Urge Incontinence: A Randomized Double-Blind Controlled Trial

Journal of Obstetrics and Gynaecology Canada

Volumn 35, Issue 1, 2013, Pages 53-60

  Jabs, Corrine ^a   Carleton, Erica ^b  

^a REGINA QU APPELLE HEALTH REGION   (Canada)

^b SAINT MARY S UNIVERSITY   (Canada)

Author keywords

Botulinum toxin A; Intradetrusor injections; Non neurogenic urinary urge incontinence; Randomized control trial

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ADULT; ARTICLE; BLADDER CAPACITY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYSTOSCOPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATURIA; HUMAN; PAIN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SIDE EFFECT; TAKOTSUBO CARDIOMYOPATHY; URGE INCONTINENCE; URINARY HESITANCY; URINARY TRACT INFECTION; URINE FLOW RATE; AGED; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; OVERACTIVE BLADDER; TREATMENT OUTCOME;

AGED; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PLACEBOS; QUALITY OF LIFE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 84907007162     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)31049-5     Document Type: Article

References (20)

1. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327-336.
2. Campbell J.D., Gries K.S., Watanabe J.H., Ravelo A., Dmochowski R.R., Sullivan S.D. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urology 2009, 9:18.
3. Flynn M.K., Amundsen C.L., Perevich M., Liu F., Webster G.D. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009, 181:2608-2615.
4. Shamliyan T., Wyman J.F., Ramakrishnan R., Sainfort F., Kane R.L. Benefits and harms of pharmacologic treatment for urinary incontinence in women. Ann Intern Med 2012, 156:86-94.
5. Botox botulinum toxin A: The medical uses of Botox 2006, Allergan, Inc, Irvine, CA.
6. Schurch B., Hauri D., Rodic B., Curt A., Meyer M., Rossier A.B. Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 1996, 155:1023-1029.
7. Kalsi V., Apostolidis A., Popat R., Gonzales G., Fowler C.J., Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006, 49:528-535.
8. Sahai A., Khan M.S., Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007, 177:2231-2236.
9. Rajkumar G.N., Small D.R., Mustafa A.W., Conn G. A prospective study to evaluate the safety, tolerability, efficacy, and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity. BJU Int 2005, 96:848-852.
10. Schurch B., de Seze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174:196-200.
11. Patki P.S., Hamid R., Arumugam K., Julian P., Shah P.J., Craggs M. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006, 98:77-82.
12. Smith C.P., Nishiguchi J., O'Leary M., Yoshimura N., Chancellor M.B. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology 2005, 65:37-41.
13. Brubaker L., Richter H.E., Visco A., Mahajan S., Nygaard I., Braun T.M., et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008, 180:217-222.
14. Dmochowski R., Chapple C., Nitti V.W., Chancellor M., Everaert K., Thompson C., et al. Efficacy and safety of OnabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010, 184:2416-2422.
15. Kuo H.C., Liao C.H., Chung S.D. Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010, 58:919-926.
16. Anger J.T., Weinberg A., Suttorp M., Litwin M.S., Shekelle P.G. Outcomes of intravesical botulinum toxin for idiopathic overactive bladder symptoms: a systematic review of the literature. J Urol 2010, 193:2258-2264.
17. Karantanis E., Allen W., Stevermuer T.L., Simons A.M., O'Sullivan R., Moore K.H. The repeatability of the 24-hour pad test. Int Urogynecol J Pelvic Floor Dysfunct 2005, 16:63-68.
18. Coyne K.S., Matza L.S., Kopp Z., Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006, 49:1079-1086.
19. Uebersax J.S., Wyman J.F., Shumaker S.A., McClish D.K. Short forms to assess life quality and symptom distress for urinary incontinence in women: the incontinence impact questionnaire and the urogenital distress inventory. Neurourol Urodyn 1995, 14:131-139.
20. Nixon A., Colman S., Sbounjian L., Sandage B., Schwiderski U.E., Staskin D.R., et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. J Urol 2005, 174:604-607.